Phio Pharmaceuticals (Phio Pharmaceuticals) Debt-to-Equity : 0.01 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Phio Pharmaceuticals Debt-to-Equity?

Phio Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.04 Mil. Phio Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Phio Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $7.73 Mil. Phio Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Phio Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

PHIO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.09
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Phio Pharmaceuticals was 0.09. The lowest was 0.01. And the median was 0.02.

PHIO's Debt-to-Equity is ranked better than
99.91% of 1072 companies
in the Biotechnology industry
Industry Median: 0.145 vs PHIO: 0.01

Phio Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Phio Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals Debt-to-Equity Chart

Phio Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.09

0.05

0.01

0.02

0.01

Phio Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.02	0.01	0.01	0.01

Competitive Comparison of Phio Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Phio Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phio Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Debt-to-Equity falls into.

Phio Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Phio Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.035	+	0)	/	7.73
	=	0.00

Phio Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.035	+	0)	/	7.73
	=	0.00

Phio Pharmaceuticals (NAS:PHIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Phio Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Phio Pharmaceuticals (Phio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (NAS:PHIO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752

Website

https://www.phiopharma.com

Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.

Executives

Robert J Bitterman	director	C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Robert L Ferrara	director	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Patricia A Bradford	director	UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Gerrit Dispersyn	officer: Chief Development Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
John A Barrett	officer: Chief Development Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Geert Cauwenbergh	director, officer: President and CEO	1 STULTS DRIVE, PLAINSBORO NJ 08536
Alexey Eliseev	officer: Chief Business Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Jonathan E Freeman	director	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Curtis Lockshin	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
H. Paul Dorman	director	1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Opko Health, Inc.	10 percent owner	4400 BISCAYNE BLVD., MIAMI FL 33137
Advanced Rna Technologies, Llc	10 percent owner	1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Keith L Brownlie	director	777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Pamela Pavco	officer: Chief Development Officer	C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581
Caitlin Kontulis	officer: Secretary and Controller	1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581